Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus
2007

Cryospray Ablation for Esophageal Cancer

Sample size: 1 publication Evidence: low

Author Information

Author(s): Cash Brooks D, Johnston Lavonne R, Johnston Mark H

Primary Institution: National Naval Medical Center, Bethesda, MD

Hypothesis

Can cryospray ablation (CSA) be an effective palliative treatment for recurrent squamous cell carcinoma of the esophagus?

Conclusion

Endoscopic cryo spray ablation warrants further investigation as a palliative treatment modality for esophageal cancer.

Supporting Evidence

  • The patient achieved complete remission for 24 months after treatment.
  • Cryospray ablation is a novel technique for treating esophageal cancer.
  • The patient was not a candidate for surgery or radiation due to comorbidities.

Takeaway

A 73-year-old man with esophageal cancer was treated with a special freezing technique called cryospray ablation, and he has been cancer-free for two years.

Methodology

The patient underwent endoscopic cryospray ablation using liquid nitrogen to treat recurrent squamous cell carcinoma.

Potential Biases

Potential bias due to the authors' involvement in the development of the CSA device.

Limitations

This is a single case report, limiting the generalizability of the findings.

Participant Demographics

73-year-old African American male.

Digital Object Identifier (DOI)

10.1186/1477-7819-5-34

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication